Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 3,483

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Vascular endothelial growth factor (VEGF) and its receptors

NEUFELD, GERA, COHEN, TZAFRA, GENGRINOVITCH, STELA, POLTORAK, ZOYA·1999·The FASEB Journal
DOI 10.1096/fasebj.13.1.9
Open this paper in CoChat — free account

Abstract

Vascular endothelial growth factor (VEGF) is a highly specific mitogen for vascular endothelial cells. Five VEGF isoforms are generated as a result of alternative splicing from a single VEGF gene. These isoforms differ in their molecular mass and in biological properties such as their ability to bind to cell‐surface heparan‐sulfate proteoglycans. The expression of VEGF is potentiated in response to hypoxia, by activated oncogenes, and by a variety of cytokines. VEGF induces endothelial cell proliferation, promotes cell migration, and inhibits apoptosis. In vivo VEGF induces angiogenesis as well as permeabilization of blood vessels, and plays a central role in the regulation of vasculogenesis. Deregulated VEGF expression contributes to the development of solid tumors by promoting tumor angiogenesis and to the etiology of several additional diseases that are characterized by abnormal angiogenesis. Consequently, inhibition of VEGF signaling abrogates the development of a wide variety of tumors. The various VEGF forms bind to two tyrosine‐kinase receptors, VEGFR‐1 ( flt‐1 ) and VEGFR‐2 ( KDR/flk‐1) , which are expressed almost exclusively in endothelial cells. Endothelial cells express in addition the neuropilin‐1 and neuropilin‐2 coreceptors, which bind selectively to the 165 amino acid form of VEGF (VEGF 165 ). This review focuses on recent developments that have widened considerably our understanding of the mechanisms that control VEGF production and VEGF signal transduction and on recent studies that have shed light on the mechanisms by which VEGF regulates angiogenesis.—Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9–22 (1999)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1096/fasebj.13.1.9

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 171

  1. 10.1073/pnas.86.19.7311 · DOI · Paper page
  2. 10.1016/0006-291X(89)92678-8 · DOI · Paper page
  3. 10.1126/science.6823562 · DOI · Paper page
  4. 10.1126/science.2479987 · DOI · Paper page
  5. 10.1126/science.2479986 · DOI · Paper page
  6. 10.1016/0006-291X(89)92729-0 · DOI · Paper page
  7. 10.1016/S0021-9258(17)45395-6 · DOI · Paper page
  8. Plouet J., 1990, Characterization of the receptor to vasculotropin on bovine adrenal cortex‐derived capillary endothelial cells, J. Biol. Chem., 265, 22071, 10.1016/S0021-9258(18)45668-2 · DOI
  9. 10.1126/science.1312256 · DOI · Paper page
  10. 10.1016/0006-291X(92)90483-2 · DOI · Paper page
  11. 10.1172/JCI116450 · DOI · Paper page
  12. 10.1210/endo.133.2.7688292 · doi:10.1210/endo.133.2.7688292 · Paper page
  13. 10.1038/367576a0 · DOI · Paper page
  14. 10.1038/359845a0 · DOI · Paper page
  15. 10.1056/NEJM199412013312203 · DOI · Paper page
  16. 10.1016/S0002-9394(14)75794-0 · DOI · Paper page
  17. 10.1073/pnas.88.20.9267 · DOI · Paper page
  18. 10.1016/S0955-0674(98)80137-3 · DOI · Paper page
  19. 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H · DOI
  20. 10.1002/(SICI)1097-4652(199711)173:2<206::AID-JCP22>3.0.CO;2-C · DOI · Paper page
  21. Brown L. F., 1997, Regulation of Angiogenesis, 233, 10.1007/978-3-0348-9006-9_10 · DOI · Paper page
  22. 10.1038/386671a0 · DOI · Paper page
  23. 10.1038/380439a0 · DOI · Paper page
  24. 10.1038/380435a0 · DOI · Paper page
  25. 10.1016/S0092-8674(00)80283-4 · DOI · Paper page
  26. 10.1182/blood.V87.8.3336.bloodjournal8783336 · DOI · Paper page
  27. Seetharam L., 1995, A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor (VEGF), Oncogene, 10, 135
  28. 10.1523/JNEUROSCI.15-07-04738.1995 · DOI · Paper page
  29. 10.1073/pnas.92.3.905 · DOI · Paper page
  30. 10.1038/nm1095-1024 · DOI · Paper page
  31. Benjamin L. E., 1998, A plasticity window for blood vessel remodelling is defined by pericyte coverage of the pre‐formed endothelial network and is regulated by PDGF‐B and VEGF, Development, 125, 1591, 10.1242/dev.125.9.1591 · DOI · Paper page
  32. 10.1001/archopht.1996.01100140419009 · DOI · Paper page
  33. Stone J., 1996, Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity, Invest. Ophthalmol. Visual Sci., 37, 290
  34. Peer J., 1995, Hypoxia‐induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases, Lab. Invest., 72, 638
  35. 10.1159/000268033 · DOI
  36. Okamoto N., 1997, Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization, Am. J. Pathol., 151, 281
  37. 10.1073/pnas.92.17.7657 · DOI · Paper page
  38. 10.1038/nm0398-336 · DOI · Paper page
  39. Folkman J., 1998, Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence, Endocrinology, 139, 441, 10.1210/endo.139.2.5858 · DOI
  40. 10.1016/S0092-8674(00)80108-7 · DOI · Paper page
  41. 10.1093/jnci/82.1.4 · DOI · Paper page
  42. 10.1083/jcb.140.4.947 · DOI · Paper page
  43. Roberts W. G., 1997, Neovasculature induced by vascular endothelial growth factor is fenestrated, Cancer Res., 57, 765
  44. 10.1002/jlb.59.1.100 · DOI · Paper page
  45. Dvorak H. F., 1992, Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation, Ann. N.Y. Acad. Sci., 667, 110, 10.1111/j.1749-6632.1992.tb51603.x · DOI
  46. 10.1074/jbc.270.43.25915 · DOI · Paper page
  47. Rak J., 1995, Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis, Cancer Res., 55, 4575
  48. Kieser A., 1994, Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression, Oncogene, 9, 963
  49. 10.1074/jbc.271.41.25492 · DOI
  50. 10.1073/pnas.94.24.13203 · DOI
  51. 10.1038/nm1296-1371 · DOI · Paper page
  52. 10.1016/S0092-8674(00)80398-0 · DOI · Paper page
  53. Millauer B., 1996, Dominant‐negative inhibition of Flk‐1 suppresses the growth of many tumor types in vivo, Cancer Res, 56, 1615
  54. 10.1038/nm1197-1222 · DOI · Paper page
  55. 10.1097/01.iae.0000246884.76018.63 · DOI · Paper page
  56. 10.1073/pnas.90.22.10705 · DOI · Paper page
  57. Lin P. N., 1998, Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor, Cell Growth Differ., 9, 49
  58. 10.1073/pnas.93.16.8502 · DOI · Paper page
  59. Saleh M., 1996, Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence, Cancer Res., 56, 393
  60. Ramakrishnan S., 1996, Vascular endothelial growth factor‐toxin conjugate specifically inhibits KDR/flk‐1‐positive endothelial cell proliferation in vitro and angiogenesis in vivo, Cancer Res., 56, 1324
  61. 10.1073/pnas.95.8.4625 · DOI
  62. Rockwell P., 1995, in vitro neutralization of vascular endothelial growth factor activation of FLK‐1 by a monoclonal antibody, Mol. Cell. Diff., 3, 91
  63. Strawn L. M., 1996, Flk‐1 as a target for tumor growth inhibition, Cancer Res., 56, 3540
  64. 10.1097/00005344-199601000-00015 · DOI
  65. 10.1161/01.RES.77.6.1077 · DOI
  66. 10.1089/hum.1996.7.8-959 · DOI
  67. 10.1089/hum.1997.8.2-215 · DOI
  68. 10.1161/01.CIR.91.11.2793 · DOI · Paper page
  69. Tsurumi Y., 1997, Treatment of acute limb ischemia by intramuscular injection of vascular endothelial growth factor gene, Circulation, 96, 382
  70. 10.1161/01.CIR.97.12.1114 · DOI · Paper page
  71. Deroanne C. F., 1997, Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up‐regulation of vascular endothelial growth factor expression, Cancer Res., 57, 5590
  72. 10.1038/sj.onc.1201219 · DOI · Paper page
  73. 10.1074/jbc.271.45.28220 · DOI · Paper page
  74. 10.1074/jbc.270.21.12607 · DOI · Paper page
  75. 10.1210/endo.137.6.8641174 · doi:10.1210/endo.137.6.8641174 · Paper page
  76. 10.1074/jbc.270.1.308 · DOI · Paper page
  77. 10.1074/jbc.271.2.736 · DOI · Paper page
  78. 10.1159/000190275 · DOI
  79. 10.1126/science.7973639 · DOI · Paper page
  80. 10.1074/jbc.271.10.5519 · DOI
  81. 10.1074/jbc.271.36.21793 · DOI · Paper page
  82. 10.1172/JCI117858 · DOI · Paper page
  83. 10.1038/sj.onc.1201201 · DOI
  84. 10.1161/01.CIR.97.1.99 · DOI · Paper page
  85. Dembinskakiec A., 1997, VEGF—nitric oxide reciprocal regulation, Nature Med., 3, 1177, 10.1038/nm1197-1177a · DOI
  86. 10.1152/ajpheart.1998.274.3.H1054 · DOI · Paper page
  87. 10.1126/science.276.5317.1423 · DOI · Paper page
  88. 10.1038/sj.onc.1201090 · DOI · Paper page
  89. 10.1016/S0021-9258(17)41787-X · DOI · Paper page
  90. 10.1074/jbc.270.22.13333 · DOI · Paper page
  91. 10.1161/01.RES.77.3.638 · DOI · Paper page
  92. Jiang B. H., 1997, V‐SRC induces expression of hypoxia‐inducible factor 1 (HIF‐1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF‐1 in tumor progression, Cancer Res., 57, 5328
  93. 10.1016/S0925-4773(97)00674-6 · DOI · Paper page
  94. 10.1128/MCB.15.10.5363 · DOI · Paper page
  95. Damert A., 1997, Up‐regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia‐driven mechanisms, Cancer Res., 57, 3860
  96. 10.1091/mbc.9.2.469 · DOI · Paper page
  97. 10.1074/jbc.273.11.6417 · DOI · Paper page
  98. Stein I., 1998, Translation of vascular endothelial growth factor mRNA by internal ribosome entry : implications for translation under hypoxia, Mol. Biol. Cell, 18, 3112, 10.1128/MCB.18.6.3112 · DOI · Paper page
  99. 10.1038/sj.onc.1202019 · DOI · Paper page
  100. 10.1097/00005792-199711000-00001 · DOI · Paper page
  101. Siemeister G., 1996, Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel‐Lindau tumor suppressor protein, Cancer Res., 56, 2299
  102. 10.1097/00005072-199711000-00009 · DOI
  103. 10.1128/MCB.17.9.5629 · DOI · Paper page
  104. 10.1073/pnas.93.20.10595 · DOI · Paper page
  105. 10.1074/jbc.272.44.27509 · DOI
  106. 10.1038/ki.1997.58 · DOI
  107. 10.1038/ng1094-171 · DOI · Paper page
  108. Mukhopadhyay D., 1995, Wild‐type p53 and v‐Src exert opposing influences on human vascular endothelial growth factor gene expression, Cancer Res., 55, 6161
  109. Agani F., 1997, p53 does not repress hypoxia‐induced transcription of the vascular endothelial growth factor gene, Cancer Res., 57, 4474
  110. 10.1210/mend-5-12-1806 · DOI · Paper page
  111. 10.1074/jbc.272.11.7151 · DOI · Paper page
  112. 10.1016/S0021-9258(18)99049-6 · DOI · Paper page
  113. 10.1091/mbc.4.12.1317 · DOI · Paper page
  114. 10.1074/jbc.270.19.11322 · DOI · Paper page
  115. 10.1073/pnas.94.22.12081 · DOI · Paper page
  116. 10.1074/jbc.272.20.13390 · DOI · Paper page
  117. 10.1093/jnci/87.3.213 · DOI · Paper page
  118. 10.3109/08977199509003209 · DOI
  119. 10.1095/biolreprod48.5.1120 · DOI · Paper page
  120. 10.1016/0002-9378(95)90335-6 · DOI
  121. 10.1074/jbc.272.39.24203 · DOI
  122. 10.1161/01.CIR.92.9.365 · DOI · Paper page
  123. 10.1016/0092-8674(95)90112-4 · DOI · Paper page
  124. 10.1016/S0021-9258(18)42666-X · DOI · Paper page
  125. 10.1038/ng0396-225 · DOI
  126. 10.1074/jbc.271.13.7788 · DOI · Paper page
  127. 10.1006/bbrc.1996.0730 · doi:10.1006/bbrc.1996.0730
  128. 10.3109/08977199709021524 · DOI
  129. 10.3109/08977199509003208 · DOI
  130. 10.1016/0092-8674(91)90010-V · DOI · Paper page
  131. Shibuya M., 1990, Nucleotide sequence and expression of a novel human receptor type tyrosine kinase gene (flt) closely related to the fms family, Oncogene, 5, 519
  132. Jussila L., 1998, Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor‐3, Cancer Res., 58, 1599
  133. Fournier E., 1997, Receptors for factors of the VEGF family, Bull. Cancer, 84, 397
  134. 10.1095/biolreprod51.3.524 · DOI
  135. 10.1006/bbrc.1995.1492 · doi:10.1006/bbrc.1995.1492
  136. Katoh O., 1995, Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation, Cancer Res., 55, 5687
  137. 10.1523/JNEUROSCI.16-19-06089.1996 · DOI · Paper page
  138. 10.1074/jbc.273.4.2090 · DOI
  139. 10.1006/bbrc.1993.1106 · DOI
  140. 10.3109/08977199409046916 · DOI
  141. 10.1038/sj.onc.1201047 · DOI · Paper page
  142. 10.1161/01.CIR.94.7.1647 · DOI · Paper page
  143. 10.1006/dbio.1996.9993 · DOI
  144. Barleon B., 1997, Vascular endothelial growth factor up‐regulates its receptor fms‐like tyrosine kinase 1 (FLT‐1) and a soluble variant of FLT‐1 in human vascular endothelial cells, Cancer Res., 57, 5421
  145. 10.1074/jbc.271.10.5638 · DOI · Paper page
  146. 10.1016/S0969-2126(97)00284-0 · DOI
  147. 10.1016/S0092-8674(00)80456-0 · DOI · Paper page
  148. 10.1074/jbc.273.18.11197 · DOI · Paper page
  149. 10.1006/bbrc.1996.1355 · DOI · Paper page
  150. 10.1002/j.1460-2075.1996.tb00872.x · DOI · Paper page
  151. 10.1074/jbc.273.6.3216 · DOI
  152. 10.1074/jbc.272.16.10382 · DOI · Paper page
  153. 10.1016/S0378-1119(98)00006-7 · DOI
  154. 10.1016/S0021-9258(18)47116-5 · DOI · Paper page
  155. 10.3109/08977199609034566 · DOI · Paper page
  156. 10.1016/S0092-8674(00)81402-6 · DOI · Paper page
  157. 10.1074/jbc.272.51.32521 · DOI · Paper page
  158. 10.1002/jcp.1041530317 · DOI · Paper page
  159. 10.1016/0006-291X(91)91276-I · DOI · Paper page
  160. 10.1006/mvre.1997.2056 · DOI · Paper page
  161. 10.1126/science.270.5241.1500 · DOI · Paper page
  162. 10.1074/jbc.271.10.5761 · DOI · Paper page
  163. 10.1074/jbc.272.50.31582 · DOI · Paper page
  164. 10.1016/S0092-8674(00)80534-6 · DOI · Paper page
  165. 10.1016/S0092-8674(00)80535-8 · DOI · Paper page
  166. 10.1074/jbc.273.35.22272 · DOI · Paper page
  167. 10.1016/S0896-6273(00)80392-X · DOI · Paper page
  168. 10.1074/jbc.271.30.17629 · DOI · Paper page
  169. Omura T., 1997, Identification of a 190‐kDa vascular endothelial growth factor 165 cell surface binding protein on a human glioma cell line, J. Biol. Chem., 272, 23317, 10.1074/jbc.272.37.23317 · DOI
  170. 10.1007/978-3-0348-9006-9_1 · DOI · Paper page
  171. 10.1016/S0896-6273(00)80371-2 · DOI · Paper page

Cited by

See all 3,483

Metadata

Authors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z.
Venue
The FASEB Journal
Publisher
Wiley
Published
1999-01
Volume
13
Issue
1
Pages
9-22
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
DOI
10.1096/fasebj.13.1.9
OpenAlex
W2141046053
Cited by
3,483
References
11
FWCI
67.31
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Funders
  • Israel Academy of Sciences and Humanities
  • Israel Cancer Research Fund

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vascular endothelial growth factor (VEGF) and its receptors. https://app.cochat.ai/papers/10.1096/fasebj.13.1.9
The paper
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. The FASEB Journal. https://doi.org/10.1096/fasebj.13.1.9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.